Your browser doesn't support javascript.
loading
The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis.
Asada, Mizuho; Mikami, Takahisa; Niimura, Takahiro; Zamami, Yoshito; Uesawa, Yoshihiro; Chuma, Masayuki; Ishizawa, Keisuke.
Afiliación
  • Asada M; Department of Pharmacy, Medical Hospital, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
  • Mikami T; Department of Neurology, Tufts Medical Center, Boston, Massachusetts, USA, taka.mikami.tmd@gmail.com.
  • Niimura T; Tufts University School of Medicine, Boston, Massachusetts, USA, taka.mikami.tmd@gmail.com.
  • Zamami Y; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Uesawa Y; Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
  • Chuma M; Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Ishizawa K; Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan.
Oncology ; 99(4): 256-259, 2021.
Article en En | MEDLINE | ID: mdl-33477139
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neumonía / Antineoplásicos Inmunológicos / Nivolumab / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Oncology Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neumonía / Antineoplásicos Inmunológicos / Nivolumab / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: America do norte Idioma: En Revista: Oncology Año: 2021 Tipo del documento: Article